Table 9.
Follow-up of asymptomatic mutation carriers | RET | NF1 |
---|---|---|
Clinical and biochemical evaluation | Initial screening by the age of 11-16 years depending on the specific mutation, then every 12 months (higher penetrance) Risk of primary hyperparathyroidism and medullary thyroid carcinoma (every 12 months calcitonin, calcium, PTH if applicable) |
Initial screening by the age of 10-14 years, then every 36 months (lower penetrance) |